Center for Reducing Asthma Disparities - Northwestern University/Cook County Hospital Centers
AsthmaLung DiseasesThe purpose of this study is to characterize the relationship of social stress, coping, and self-regulatory health behaviors in the context of asthma disparities among African American and low income populations.
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva...
Pulmonary DiseaseChronic ObstructiveComparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.
Rituxmab Versus IL-6 in Treating ILD
Interstitial Lung DiseaseSclerodermaAll SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test
Creating and Assessing a Voice Dataset for Automated Classification of Chronic Obstructive Pulmonary...
Chronic Obstructive Pulmonary DiseaseThis work aims to evaluate whether voice recordings collected from patients diagnosed with COPD and healthy control groups can be used to detect the disease using machine learning techniques.
Segmentation of Structural Abnormalities in Chronic Lung Diseases
Cystic FibrosisAsthma2 moreLung structural abnormalities are complex, time-consuming, and may lack reproducibility to evaluate visually on CT scans. The study's aim is to perform automated recognition of structural abnormalities in CT scans of patients with chronic lung diseases by using dedicated software.
Remote Assessment of Lung Disease and Impact on Physical and Mental Health
Chronic Obstructive Pulmonary DiseaseInterstitial Lung Disease1 moreThis cohort study aims to use the open-source RADAR-base mHealth platform to collect and analyze datasets associated with lung disease. This will include continuous data collected from wearable devices (e.g. heart rate, oxygen saturation, respiratory rate), including pulse oximeters, spirometer, mobile phones, digital tests, and smart phone symptom questionnaires.
Tiotropium Respimat Administration With and Without Aerochamber Disease (COPD)
Chronic Obstructive Pulmonary DiseaseCOPD patient on Tiotropium Respimart divided into two group, Group A given aerochamber and Group B without aerochamber enroll in the study for total 18 week .
Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions
Pulmonary FibrosisCOVID-19 PneumoniaThis study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.
Capnography Monitoring in Ventilated Children
ChildOnly12 moreEnd-tidal CO2 measurements in children will be assessed for their accuracy with arterial CO2 measurements.
DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary DiseaseChronic ObstructiveSubjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in the past 6 months will be screened to participate in the study. Subjects will have an equal chance of being in any of the following two groups (1:1 allocation). One group will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5 to9 days), and the DISKUS inhaler at Visit 2 to use during the second period (twice daily for 5 to 9 days). The other group will be dispensed the DISKUS inhaler at Visit 1 to use during the first period (twice daily for 5 to 9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5 to9 days). At the end of the second period, subjects will complete the study by answering 7 questions to assess their preference of device attributes and dosing regimens between the two inhalers. The null hypothesis for device preference for a specific attribute is that 50% subjects express a preference in that attribute for ELLIPTA and 50% do NOT express a preference in that attribute for ELLIPTA, i.e., the odds for preferring ELLIPTA to not preferring ELLIPTA is unity. The null hypothesis for dosing regimen preference is that 50% subjects express a preference of once daily dosing and 50% do not express a preference of once daily dosing (prefer twice daily dosing or have no preference).